GURU.Markets stock price, segment price, and overall market index valuation
The company's share price scPharmaceuticals Inc.
scPharmaceuticals has developed a device for subcutaneous administration of furosemide, allowing for the treatment of heart failure at home. Its stock price reflects the success of commercializing this product. The chart is a history of innovations aimed at reducing hospital costs.
Share prices of companies in the market segment - Pharma other
scPharmaceuticals (SCPH) specializes in developing subcutaneous medications that are traditionally administered intravenously, enabling treatment outside the hospital. We classify it as "Other Pharmaceuticals." The chart below shows the dynamics of the innovative drug delivery systems sector.
Broad Market Index - GURU.Markets
scPharmaceuticals is a pharmaceutical company developing subcutaneous forms of drugs traditionally administered intravenously in hospitals. As part of the GURU.Markets index, it aims to bring treatment to the home. The chart below represents the entire market. See how scPharma shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SCPH - Daily change in the company's share price scPharmaceuticals Inc.
scPharmaceuticals shares exhibit high volatility. Change_co measures market reactions to the commercial launch of its drugs and insurance company decisions. This metric is an important component of the formulas on System.GURU.Markets, which evaluate young pharmaceutical companies at the product launch stage.
Daily change in the price of a set of shares in a market segment - Pharma other
scPharmaceuticals Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to SCPH, which focuses on subcutaneous injections, helps assess its unique risk profile in this niche.
Daily change in the price of a broad market stock, index - GURU.Markets
scPharmaceuticals is a pharmaceutical company specializing in subcutaneous formulations of drugs traditionally administered intravenously. The pharmaceutical sector is known for its high volatility. The chart below reflects average daily fluctuations in this industry, allowing one to assess how scPharmaceuticals' performance compares to overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization scPharmaceuticals Inc.
scPharmaceuticals' year-over-year performance is a story of the transition from hospital-based injections to self-administration at home. Its market capitalization growth over the past 12 months reflects the successful commercialization of its device, which allows patients with heart failure to self-administer furosemide, reducing costs and improving quality of life.
Annual dynamics of market capitalization of the market segment - Pharma other
scPharmaceuticals Inc. is a pharmaceutical company developing injectable medications that can be administered at home. Its technology is aimed at reducing healthcare costs. The chart shows how its innovative delivery model and regulatory decisions are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
scPharmaceuticals is a biopharmaceutical company whose stock performance is driven by the commercialization of its products and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization scPharmaceuticals Inc.
scPharmaceuticals' market capitalization depends on its product cycle. Monthly fluctuations on the chart reflect the commercial launch of its subcutaneous furosemide injector, the success of which is crucial to its future, making the stock highly news-sensitive.
Monthly dynamics of market capitalization of the market segment - Pharma other
scPharmaceuticals has developed a device that allows for the subcutaneous administration of drugs that typically require intravenous infusion in the hospital, specifically furosemide for the treatment of heart failure. The company's success depends on the transition to home treatment. The pharmaceutical sector chart provides a general background against which the potential of scPharmaceuticals' innovative delivery system can be seen.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
scPharmaceuticals develops drugs for subcutaneous administration. The company's shares move in sync with FDA news and commercial product launches. Their performance is completely disconnected from the broader market and is a bet on success in a narrow pharmaceutical niche.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization scPharmaceuticals Inc.
scPharmaceuticals has developed a device for subcutaneous administration of popular drugs typically administered intravenously. Its weekly stock price reflects FDA approvals, agreements with insurance companies, and its ability to convince the market of the advantages of its drug delivery method.
Weekly dynamics of market capitalization of the market segment - Pharma other
Pharmaceutical companies developing new drug delivery systems, like scPharmaceuticals, are solving a common industry problem. The chart below shows the market sentiment in this niche. It allows one to assess how promising the market perceives scPharmaceuticals' subcutaneous drug delivery technology compared to its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
scPharmaceuticals has developed a device for subcutaneous administration of common intravenous medications, enabling treatment at home. The chart below shows how investors view the potential of this innovation, and how much its performance depends on news about its implementation rather than the market.
Market capitalization of the company, segment and market as a whole
SCPH - Market capitalization of the company scPharmaceuticals Inc.
The scPharmaceuticals market capitalization chart represents investor valuation of its heart failure treatment product. Its dynamics reflect the market's appreciation of its drug, FUROSCIX, which allows furosemide to be administered subcutaneously at home. This growth suggests potential for reduced hospitalizations and healthcare costs.
SCPH - Share of the company's market capitalization scPharmaceuticals Inc. within the market segment - Pharma other
scPharmaceuticals has developed an innovative system for subcutaneous administration of drugs that traditionally require intravenous injections. Its market capitalization in the pharmaceutical sector reflects the potential of this technology to transform drug delivery, moving treatment from the hospital to the home. The company's value is a bet on convenience and cost savings for the healthcare system.
Market capitalization of the market segment - Pharma other
Below is a graph showing the total value of the entire pharmaceutical sector. For scPharmaceuticals, with its innovative subcutaneous drug delivery system, this line represents the future of drug delivery. The rising graph shows how the industry is seeking ways to make treatments more convenient and affordable, moving them from hospitals to patients' homes.
Market capitalization of all companies included in a broad market index - GURU.Markets
scPharmaceuticals has developed subcutaneous forms of drugs typically administered intravenously. Its market capitalization is based on its convenience and savings for the healthcare system. This market share is determined by the company's ability to move treatment from the hospital to the home.
Book value capitalization of the company, segment and market as a whole
SCPH - Book value capitalization of the company scPharmaceuticals Inc.
scPharmaceuticals has developed a device for subcutaneous administration of furosemide. Its book value is its financial resources and product inventory. It consists of cash for commercial launch and finished FUROSCIX devices. How did this capital change at the start of sales? The chart below shows.
SCPH - Share of the company's book capitalization scPharmaceuticals Inc. within the market segment - Pharma other
scPharmaceuticals Inc. develops drugs for subcutaneous administration. Its innovations require the necessary resources to manufacture its patented infusion devices and the drug itself. The chart shows the company's share of the physical infrastructure required to create new drug delivery systems.
Market segment balance sheet capitalization - Pharma other
scPharmaceuticals, a biopharmaceutical company, has a relatively lightweight model. It focuses on developing its subcutaneous drug delivery system and has outsourced a significant portion of its manufacturing. The BCap_Seg chart for the biotech sector serves as a backdrop, showing the varying levels of capital intensity.
Book value of all companies included in the broad market index - GURU.Markets
scPharmaceuticals' balance sheet is based on its technology and patents for subcutaneous formulations of drugs traditionally administered intravenously, such as furosemide. The company's assets are its intellectual property. The chart shows how this "drug delivery innovator" stacks up against major pharmaceutical companies in terms of assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - scPharmaceuticals Inc.
scPharmaceuticals' balance sheet is its R&D capital. Its entire market value is a premium for its device, which allows for subcutaneous rather than intravenous administration of drugs. The schedule is a bet that this technology will be adopted by hospitals to save money.
Market to book capitalization ratio in a market segment - Pharma other
scPharmaceuticals has developed a device for subcutaneous drug administration at home. The chart shows how investors view its technology, which could reduce healthcare costs by moving treatment from the hospital to the home, a significant trend.
Market to book capitalization ratio for the market as a whole
scPharmaceuticals develops subcutaneous medications typically administered intravenously. Its value lies in its convenience and cost savings for the healthcare system. Its market valuation reflects the potential of its products to change treatment standards. The chart shows this valuation compared to its balance sheet.
Debts of the company, segment and market as a whole
SCPH - Company debts scPharmaceuticals Inc.
scPharmaceuticals, a company developing subcutaneous delivery systems for approved drugs, is using capital to commercialize its products. This chart shows how the company is funding its market entry, aiming to offer patients and hospitals a more convenient and affordable alternative to intravenous infusions.
Market segment debts - Pharma other
scPharmaceuticals has developed a system for subcutaneous administration of drugs typically administered intravenously. Commercializing such a product requires significant production and marketing costs. This chart shows how the company finances its product launch and how much it relies on debt during this critical stage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio scPharmaceuticals Inc.
scPharmaceuticals develops devices for subcutaneous drug delivery, which could change the treatment of many diseases. This chart shows the company's reliance on external funding to bring its products to market. It reflects the financial risks associated with the approval and commercialization of innovative medical solutions.
Market segment debt to market segment book capitalization - Pharma other
scPharmaceuticals has developed a method for subcutaneous administration of furosemide, allowing heart failure patients to receive treatment at home rather than in the hospital. The chart shows the debt burden in the pharmaceutical industry, providing context for assessing how the company is financing the commercialization of its niche product.
Debt to book value of all companies in the market
scPharmaceuticals Inc. is developing subcutaneous delivery systems for drugs traditionally administered intravenously, which could change the standard of care. This chart, reflecting the overall debt burden in the market, provides context. It helps assess how the company finances its innovations and how its financing strategy compares to the pharmaceutical sector.
P/E of the company, segment and market as a whole
P/E - scPharmaceuticals Inc.
scPharmaceuticals has developed a device for subcutaneous administration of furosemide at home, thereby avoiding hospitalization for heart failure. This chart shows how the market is evaluating its innovative solution. The trend reflects the potential for shifting treatment from the hospital to the home, which could significantly reduce healthcare costs.
P/E of the market segment - Pharma other
scPharmaceuticals has developed a device for the home treatment of heart failure. This chart shows the average valuation for the pharmaceutical sector. It helps understand how investors value its product, which could reduce healthcare costs, and how this valuation compares to the industry average.
P/E of the market as a whole
scPharmaceuticals Inc. is a pharmaceutical company developing and commercializing subcutaneous products that enable drug delivery outside of the hospital. This chart reflects the overall sentiment in the pharmaceutical sector. It helps understand whether SCPH's valuation reflects faith in its innovative drug delivery platform or whether it is moving in line with overall market trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company scPharmaceuticals Inc.
scPharmaceuticals has developed a device for subcutaneous administration of commonly used intravenous medications, enabling home treatment. This graph reflects market expectations regarding the shift in healthcare from hospital-based to home-based treatment and the commercial success of its innovative products.
%20P%2FE%20scPharmaceuticals%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-scPharmaceuticals-Inc.&v=1772646533367 "Chart of the company's future (projected) P/E scPharmaceuticals Inc.")
Future (projected) P/E of the market segment - Pharma other
scPharmaceuticals has developed a device that allows for the subcutaneous administration of drugs traditionally administered intravenously, such as furosemide for the treatment of heart failure. This chart reflects expectations for its future profitability, demonstrating whether analysts believe its technology can move treatment from the hospital to the home.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772646533368 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
scPharmaceuticals has developed a subcutaneous method for administering drugs that typically require intravenous injections. This increases convenience for patients. This graph of overall market expectations demonstrates how much investors value innovations that don't create new molecules, but rather improve the delivery methods of existing drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772646533380 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit scPharmaceuticals Inc.
scPharmaceuticals has developed a method for subcutaneous administration of commonly used intravenous medications, enabling treatment at home. This graph shows the commercialization path for this innovation. Revenue growth depends on the acceptance of this new, more convenient drug delivery method by physicians and patients.
Profit of companies in the market segment - Pharma other
scPharmaceuticals has developed a device that allows for subcutaneous administration of drugs typically administered intravenously, enabling home treatment. Its business model is aimed at reducing healthcare costs. Future profitability depends on the adoption of this technology by physicians and patients.
Overall market profit
scPharmaceuticals is a pharmaceutical company developing subcutaneous forms of drugs traditionally administered intravenously. This enables home-based treatment. Its success depends on the acceptance of this model by doctors and patients. The overall economic situation, reflected in the graph, influences healthcare systems and their desire to reduce costs, which may be an argument in favor of scPharmaceuticals' technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company scPharmaceuticals Inc.
scPharmaceuticals has developed a subcutaneous formulation of furosemide for the treatment of edema in patients with heart failure outside the hospital. This graph reflects analysts' expectations for future revenue. The forecast depends on the successful commercial launch of their product, FUROSCIX, and its acceptance by physicians and payers as an alternative to hospitalization.
%20profit%20of%20the%20company%20scPharmaceuticals%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-scPharmaceuticals-Inc.&v=1772646533409 "Graph of future (projected) profit of the company scPharmaceuticals Inc.")
Future (predicted) profit of companies in the market segment - Pharma other
scPharmaceuticals has developed a method for subcutaneous administration of widely used intravenous medications, enabling home treatment. The profitability projections for the pharmaceutical industry, shown in the graph, highlight the industry's drive to reduce healthcare costs. This chart helps assess the potential of scPharmaceuticals' technology to transform treatment standards.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772646533411 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
scPharmaceuticals is developing subcutaneous medications that can be administered at home instead of intravenous injections in the hospital. This model has the potential to reduce healthcare costs. Its success depends on regulatory approval and physician acceptance, which are less dependent on the short-term economic cycles visible in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772646533411 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - scPharmaceuticals Inc.
scPharmaceuticals has developed a device for subcutaneous administration of furosemide, allowing heart failure patients to receive treatment at home. This chart shows how investors estimate the revenue from this innovative product. This figure reflects the potential to reduce hospitalization costs and improve patients' quality of life.
P/S market segment - Pharma other
scPharmaceuticals develops and commercializes products for subcutaneous administration of drugs traditionally administered intravenously, enabling home treatment. This chart shows the average revenue estimate for the pharmaceutical industry. It helps assess the market's appreciation for innovations aimed at improving patient convenience and reducing costs.
P/S of the market as a whole
scPharmaceuticals has developed a device that allows for the subcutaneous administration of drugs traditionally administered intravenously. Its first product is designed to treat edema in patients with heart failure. The chart below compares how the market values the company's revenue with its innovative drug delivery system.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company scPharmaceuticals Inc.
scPharmaceuticals has developed a device for subcutaneous administration of furosemide for the treatment of heart failure at home. This chart shows how investors estimate its future earnings. This estimate is a bet that its product will reduce hospitalizations and become popular.
%20P%2FS%20scPharmaceuticals%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-scPharmaceuticals-Inc.&v=1772646533478 "The graph of the company's future (projected) P/S scPharmaceuticals Inc.")
Future (projected) P/S of the market segment - Pharma other
scPharmaceuticals develops products for subcutaneous administration of drugs traditionally administered intravenously. This chart compares market expectations for its future revenue with those of other pharmaceutical companies. This valuation reflects investors' confidence in its ability to shift treatment from hospital to home settings, reducing healthcare costs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772646533492 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
scPharmaceuticals is a pharmaceutical company developing subcutaneous medications that can be administered at home instead of intravenous injections in the hospital. Its success depends on the convenience and cost-effectiveness of its products. This overall expectation is less important to scPharmaceuticals than the ability of its technology to reduce healthcare costs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772646533505 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales scPharmaceuticals Inc.
This chart illustrates the revenue of scPharmaceuticals, a company that developed a device for subcutaneous administration of furosemide, a drug used to treat heart failure. This allows patients to receive treatment at home rather than in the hospital. Revenue growth reflects the commercial launch of this product and its acceptance by doctors and patients as a convenient and cost-effective alternative.
Sales of companies in the market segment - Pharma other
scPharmaceuticals developed and commercialized Furoscix, a product that allows for subcutaneous administration of furosemide at home to treat edema in patients with heart failure. This chart shows revenues in the other pharmaceuticals sector. It reflects the trend toward shifting treatment from the hospital to the home, reducing costs and improving patients' quality of life.
Overall market sales
scPharmaceuticals has developed a device for subcutaneous administration of furosemide, allowing for the treatment of edema outside the hospital. Demand for this product depends on its ability to reduce healthcare costs by preventing hospitalizations. The overall economic situation, illustrated in this chart, is driving the search for such cost-effective solutions.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company scPharmaceuticals Inc.
scPharmaceuticals is a pharmaceutical company specializing in the development of subcutaneous medications for at-home use. This projected revenue chart reflects the commercial launch of its flagship product. This increase is driven by expectations for the successful launch and acceptance of its innovative drug delivery system by physicians and patients.
%20sales%20of%20the%20company%20scPharmaceuticals%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-scPharmaceuticals-Inc.&v=1772646533522 "Schedule of future (projected) sales of the company scPharmaceuticals Inc.")
Future (projected) sales of companies in the market segment - Pharma other
scPharmaceuticals has developed and commercialized a device for subcutaneous administration of furosemide, allowing patients with heart failure to receive treatment at home instead of hospitalization. This graph shows projected revenues for the entire pharmaceutical sector, reflecting the trend toward shifting treatment from hospital to home settings.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772646533537 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
scPharmaceuticals develops subcutaneous medications for use outside the hospital. Its business model is aimed at reducing healthcare system costs. Sustainable economic growth is important because it allows healthcare systems to invest in innovations that improve patient convenience and reduce the overall burden on hospitals.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772646533539 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality scPharmaceuticals Inc.
scPharmaceuticals develops and commercializes drugs that can be administered subcutaneously at home. Its goal is to reduce hospitalization costs. The profitability chart demonstrates the company's success in convincing physicians and insurance companies of the cost-effectiveness of its approach, which is key to commercial success.
Market segment marginality - Pharma other
scPharmaceuticals has developed and commercialized a device for subcutaneous administration of furosemide at home, providing an alternative to intravenous infusions in the hospital. This graph shows the profitability of its innovative product. The ability to reduce healthcare costs by bringing treatment to the home is a key driver of its profitability potential.
Market marginality as a whole
scPharmaceuticals has developed a device that allows for subcutaneous administration of injectable medications at home, rather than intravenously in the hospital. The need to reduce healthcare costs and improve patient convenience is a long-term trend that is independent of the general economic cycles shown in this chart.
Employees in the company, segment and market as a whole
Number of employees in the company scPharmaceuticals Inc.
scPharmaceuticals has developed a technology for subcutaneous administration of drugs typically administered intravenously. This graph shows the team working on commercializing its first product. The growth of staff reflects the shift from R&D to building the commercial infrastructure to bring the drug to market.
Share of the company's employees scPharmaceuticals Inc. within the market segment - Pharma other
scPharmaceuticals develops innovative subcutaneous delivery systems for drugs typically administered intravenously. Its team consists of a small group of specialists dedicated to securing approvals and bringing products to market. This chart illustrates its focus: a minimal staff means concentrating on regulatory and commercial issues for its core products.
Number of employees in the market segment - Pharma other
scPharmaceuticals has developed a device that allows for the subcutaneous administration of medications that traditionally required intravenous injections in the hospital. This graph illustrates the trend toward shifting treatment from the hospital to the home. The company's growth reflects the potential savings for the healthcare system and convenience for patients, which are strong drivers for the adoption of this technology.
Number of employees in the market as a whole
scPharmaceuticals develops and commercializes subcutaneous medications that previously required intravenous infusions. Its staff is growing as products are brought to market. This overall employment chart highlights that innovations aimed at improving patient convenience and reducing costs for the healthcare system are a powerful growth driver in the pharmaceutical industry.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company scPharmaceuticals Inc. (SCPH)
scPharmaceuticals has developed a device that allows for the subcutaneous administration of medications that previously required intravenous injections in hospitals. This reduces costs and is convenient for patients. This graph illustrates the high cost per employee. The market is evaluating the potential of the company's technological platform to transform the delivery of many widely used medications.
%20of%20the%20company%20scPharmaceuticals%20Inc.%20(SCPH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-scPharmaceuticals-Inc.-SCPH&v=1772646533574 "Chart of market capitalization per employee (in thousands of dollars) of the company scPharmaceuticals Inc. (SCPH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
scPharmaceuticals develops and commercializes subcutaneous medications that previously required intravenous administration in hospitals. This metric reflects the market valuation of their innovative concept. A high metric indicates that investors see significant potential in shifting treatment from the hospital to the home, which is convenient for patients and beneficial for the healthcare system.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772646533586 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
scPharmaceuticals has developed a device for subcutaneous administration of popular hospital medications at home. This represents an innovation that has the potential to transform the healthcare system. The company's value lies in its ability to reduce costs and improve patient convenience, which is appreciated by the market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772646533596 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company scPharmaceuticals Inc. (SCPH)
scPharmaceuticals is a company that has developed a device for subcutaneous administration of Furosemide (for the treatment of edema in heart failure) at home. It's a niche product. This graph shows the demand for their solution. The profit per employee here reflects the profit margins of their unique drug delivery system.
%20Chart%20scPharmaceuticals%20Inc.%20(SCPH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-scPharmaceuticals-Inc.-SCPH&v=1772646533603 "Company Profit Per Employee (in thousands of dollars) Chart scPharmaceuticals Inc. (SCPH)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
scPharmaceuticals is a pharmaceutical company specializing in subcutaneous (injected under the skin) versions of existing hospital medications. Their key product is injectable furosemide. This figure reflects the effectiveness of their small team in promoting and selling this niche product, which offers convenience compared to inpatient treatment.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772646533605 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
scPharmaceuticals is a pharmaceutical company specializing in subcutaneous (injectable) delivery of existing intravenous medications. Their business isn't about discovering new molecules, but rather improving delivery methods. This chart shows how successfully their R&D and commercialization team is bringing these improved products to market, generating revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772646533618 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee scPharmaceuticals Inc. (SCPH)
scPharmaceuticals develops and commercializes products for subcutaneous administration of drugs traditionally administered intravenously. This chart illustrates their business model. The growth in revenue per employee will reflect the successful implementation of their products, which enable treatment outside the hospital.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-scPharmaceuticals-Inc.-SCPH&v=1772646533619 "Sales chart per company employee scPharmaceuticals Inc. (SCPH)")
Sales per employee in the market segment - Pharma other
scPharmaceuticals (SCPH) is a pharmaceutical company focused on developing subcutaneous (not intravenous) medications for home use. Their flagship product is Furoscix (an edema treatment). This chart shows the revenue generated by each employee. It's an indicator of the commercial success of their products, which are aimed at reducing hospital costs.
Sales per employee for the market as a whole
scPharmaceuticals (SCPH) is a pharmaceutical company focused on developing drugs for subcutaneous administration (instead of intravenous) using their FUROSCIX system (for the treatment of heart failure). This metric reflects how successfully their small commercial team is promoting this niche product to doctors and patients.
Short shares by company, segment and market as a whole
Shares shorted by company scPharmaceuticals Inc. (SCPH)
scPharmaceuticals has developed a device that allows for subcutaneous administration of a heart failure drug (furosemide) at home. This chart shows bearish bets. Bears doubt commercial success: they bet that doctors won't actively prescribe it, and patients won't use the new, expensive system.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-scPharmaceuticals-Inc.-SCPH&v=1772646533640 "Short Shares Chart for the Company scPharmaceuticals Inc. (SCPH)")
Shares shorted by market segment - Pharma other
scPharmaceuticals is developing a method for subcutaneous administration (instead of IV drips) of well-known hospital medications, such as furosemide. This figure reflects skepticism. The "short" here is a bet that their product, Furoscix, will not be used by doctors or that insurance companies will not cover it.
Shares shorted by the overall market
scPharmaceuticals has developed a system for subcutaneous administration of Furosemide at home, which helps avoid hospitalization for heart failure. This chart reflects the general market fears. A technology that saves money for the healthcare system should be in demand. But in a panic, investors may fear the slow adoption of new practices.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator scPharmaceuticals Inc. (SCPH)
scPharmaceuticals (SCPH) is a pharmaceutical company. Their main product is Furoscix, a furosemide injection (a diuretic) that heart failure patients can administer at home, avoiding hospitalization. This chart measures hype. It shows "overheated" (above 70) on news of a successful commercial launch or "oversold" (below 30) on concerns about slow adoption.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-scPharmaceuticals-Inc.-SCPH&v=1772646533672 "RSI 14 indicator chart for the company's stock scPharmaceuticals Inc. (SCPH)")
RSI 14 Market Segment - Pharma other
scPharmaceuticals (SCPH) — "home injection." Their niche is devices (Furoscix) that allow for the administration of intravenous (IV) medications (for swelling) subcutaneously (SC) at home. RSI_14_Seg for "Pharma other" (biotech) shows the overall sentiment. The chart helps us understand: is SCPH's volatility their niche or just general hype?
RSI 14 for the overall market
scPharmaceuticals (SCPH) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SCPH (scPharmaceuticals Inc.)
scPharmaceuticals (SCPH) has developed FUROSCIX, an injector for subcutaneous administration of furosemide (a diuretic) at home. This allows for the treatment of heart failure patients outside the hospital. This graph shows the analysts' average 12-month forecast, reflecting their assessment of how quickly doctors and patients will embrace this alternative to hospitalization.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SCPH-scPharmaceuticals-Inc.&v=1772646533690 "A chart showing analyst consensus forecasts for the expected stock price. SCPH (scPharmaceuticals Inc.)")
The difference between the consensus estimate and the actual stock price SCPH (scPharmaceuticals Inc.)
scPharmaceuticals is launching Furoscix, an innovative subcutaneous injection of furosemide that allows for the treatment of edema (associated with heart failure) at home. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their confidence in the product's commercial success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SCPH-scPharmaceuticals-Inc.&v=1772646533691 "A chart showing the difference between the consensus forecast and the actual stock price. SCPH (scPharmaceuticals Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma other
scPharmaceuticals is changing the game in heart failure treatment by offering Furoscix, an injector for self-administration at home instead of hospitalization. This chart shows analysts' overall expectations across the pharmaceutical sector. It reflects whether experts believe in the "hospital at home" trend and new drug delivery methods.
Analysts' consensus forecast for the overall market share price
scPharmaceuticals is a pharmaceutical company focused on developing subcutaneous medications traditionally administered intravenously. Their goal is to move treatment from the hospital to the home. This chart shows the overall risk appetite. For SCPH, as a company in the commercialization stage, overall market optimism is important for funding, but their success depends more on physician and insurer acceptance of this new model.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index scPharmaceuticals Inc.
scPharmaceuticals is a company focused not on new molecules, but on innovative delivery systems. Their flagship product, Furoscix, allows for the life-saving heart failure drug (furosemide) to be administered subcutaneously at home, avoiding hospitalization. This chart is an assessment of their commercial strategy, measuring how successfully they convince doctors and insurers of the benefits of this hospital-at-home approach.
AKIMA Market Segment Index - Pharma other
scPharmaceuticals is a pharmaceutical company focused on bringing hospital care to the home. Its key product, FUROSCIX, is a subcutaneous infuser (pump) that allows heart failure patients to administer diuretics at home. The graph shows the industry average. This benchmark helps us understand how this niche (but cost-effective) technology differentiates SCPH from the average pharmaceutical company.
The AKIM Index for the overall market
scPharmaceuticals is a pharmaceutical company focused on optimizing drug delivery. Its product, Furoscix, allows heart failure to be treated at home, avoiding hospitalization. This chart, reflecting the market average, provides context. It helps assess how this healthcare efficiency story compares to overall macroeconomic trends.
